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Abstract
Background: Cryptosporidium parvum, the protozoan parasite, causes a significant enteric disease
in immunocompromised hosts such as HIV patients. The present study was aimed to compare
serum IgG, IgM and IgA responses to crude soluble antigen of C. parvum in HIV seropositive and
seronegative patients co-infected with Cryptosporidium  and to correlate the responses with
symptomatology.
Methods: Cryptosporidium parvum specific serum antibody (IgG, IgM and IgA) responses were
assessed by ELISA in 11 HIV seropositive Cryptosporidium positive (Group I), 20 HIV seropositive
Cryptosporidium negative (Group II), 10 HIV seronegative Cryptosporidium positive (Group III), 20
HIV seronegative Cryptosporidium negative healthy individuals (Group IV) and 25 patients with other
parasitic diseases (Group V).
Results: A positive IgG and IgA antibody response was observed in significantly higher number of
Cryptosporidium  infected individuals (Gp I and III) compared to Cryptosporidium  un-infected
individuals (Gp II, IV and V) irrespective of HIV/immune status. Sensitivity of IgG ELISA in our study
was found to be higher as compared to IgM and IgA ELISA. The number of patients with positive
IgG, IgM and IgA response was not significantly different in HIV seropositive Cryptosporidium
positive patients with diarrhoea when compared to patients without diarrhoea and in patients with
CD4 counts <200 when compared to patients with CD4 counts >200 cells/μl.
Conclusion: The study showed specific serum IgG and IgA production in patients infected with
Cryptosporidium, both HIV seropositive and seronegative as compared to uninfected subjects
suggesting induction of Cryptosporidium specific humoral immune response in infected subjects.
However, there was no difference in number of patients with positive response in HIV seropositive
or seronegative groups indicating that HIV status may not be playing significant role in modulation
of Cryptosporidium specific antibody responses. The number of patients with positive IgG, IgM and
IgA response was not significantly different in patients with or without history of diarrhoea thereby
indicating that Cryptosporidium specific antibody responses may not be necessarily associated with
protection from symptomatology.
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Background
Cryptosporidium parvum, the protozoan parasite, causes a
significant enteric disease in immunocompromised hosts
such as HIV patients. Severe chronic infections may
develop in immunocompromised hosts with lymphocyte
or gammaglobulin deficiencies which suggest that both
cell mediated and humoral immune responses are
involved in resolution of infections and development of
protection [1]. Serologic surveys in immunocompetent
individuals or HIV/AIDS patients show varying levels of
anti  Cryptosporidium  antibodies. Detectable IgG levels
against Cryptosporidium were reported in 86% in Australia
[2], 26% in Britain [3], 64% in Peru [4] and 64% in Ven-
ezuela [4] in healthy individuals. A previous study [5]
reported Cryptosporidium specific positive IgG response in
5 (100%) HIV patients and 12 (100%) immunocompe-
tent patients. In another study [6] IgG antibodies were
observed in 13 out of 15 (86.7%) immunocompetent and
all the 26 (100%) AIDS patients studied and IgM response
was observed in 14 out of 15 (93.3%) immunocompetent
and 4 out of 26 (15.4%) HIV positive patients. A positive
IgG and IgM response was reported in all 16 (100%)
immunocompetent and 24 (100%) AIDS patients studied
[7]. In a similar study [8] positive IgG, IgM and IgA
response was observed in all the 4 (100%) immunocom-
petent and 4 (100%) HIV positive patients, studied. The
role of antibody responses in protection is still not clear.
In the study conducted in Alabama [5], antibodies to
Cryptosporidium were detected in sera from 5 AIDS subjects
with persistent cryptosporidiosis. The fact that some AIDS
patients with persistent symptomatic infection with Crypt-
osporidium have a high antibody titre to C. parvum sup-
ports the theory that specific serum antibody alone is not
sufficient to control the infection [9]. Studies comparing
the IgG, IgM and IgA response in HIV seropositive and
seronegative patients to C. parvum are scarce and reported
in very limited numbers of subjects. In India the number
of HIV infected individuals is growing at an alarming rate
with 2.47 million people infected with HIV till the end of
year 2006 [10]. Although, Cryptosporidium  has been
reported in 4.6%-12% HIV patients from different geo-
graphical areas in India [11-17], reports regarding IgG,
IgM or IgA response to C. parvum in HIV seropositive or
seronegative subjects are totally lacking. The present study
was aimed to compare serum IgG, IgM and IgA responses
to crude soluble antigen of C. parvum in HIV seropositive
and seronegative patients co-infected with Cryptosporidium
and to correlate the responses with symptomatology.
Methods
Subjects
Two hundred and six HIV seropositive, 153 HIV seroneg-
ative and 50 normal healthy individuals without any his-
tory suggestive of cryptosporidiosis were enrolled in a
previous study for detection of Cryptosporidium by stool
examination with Ziehl-Neelsen [18], safranine methyl-
ene blue staining [19], antigen detection ELISA (RIDAS-
CREEN Cryptosporidium, R-Biofarm, Germany) and a
nested PCR targeting the small subunit rRNA gene specific
for Cryptosporidium parvum [20]. Based on the results of
this study, out of the subjects detailed above, 11 HIV sero-
positive Cryptosporidium positive (Group I), 20 HIV serop-
ositive  Cryptosporidium  negative (Group II), 10 HIV
seronegative Cryptosporidium positive (Group III) and 20
HIV seronegative Cryptosporidium negative healthy indi-
viduals (Group IV) were selected for the present study,
from the Immunodeficiency clinic, the inpatient and out-
patient departments of Nehru Hospital attached to Post
Graduate Institute of Medical Education and Research,
Chandigarh, a tertiary care hospital in North India. For
determining the specificity of ELISA, 25 patients with
other parasitic infections (4 each with toxoplasmosis and
amoebiasis, 2 with ascariasis and 5 each with malaria,
hydatid and neurocysticercosis, respectively (Group V)
were also included in the study. Diagnosis of HIV was
established as per National AIDS Control Organization
(NACO) guidelines (WHO criteria adopted by NACO)
[10]. After obtaining informed consent from each individ-
ual, the demographic characters such as sex, age, history of
diarrhoea and any other relevant symptoms were
recorded on standard proforma. HIV patients receiving
anti-retroviral therapy were excluded from the study.
About 3-5 ml venous blood was collected from each
patient in vials without any anti-coagulant within 15 days
of onset of infection. The person performing the serologic
assays was not blinded to the clinical status of the
patients.
Antigens
Cryptosporidium parvum oocysts (Iowa strain) were
obtained from NIH AIDS Research and Reagent Program.
Cryptosporidium parvum crude soluble antigen was pre-
pared by sonication of oocysts with few modifications
[21]. Briefly, oocysts were washed thrice with PBS (15,000
rpm, 15 min), suspended in PBS, freeze-thawed 20 times,
sonicated (twelve cycles of 30 seconds) and centrifuged
(15,000 rpm, 15 min, 4°C). The supernatant was used as
crude soluble antigen of Cryptosporidium (CCA) after esti-
mating protein by Lowry's method.
Enzyme-linked Immunosorbent Assay (ELISA)
Serum IgG, IgM and IgA responses to Cryptosporidium
crude soluble antigen (CCA) were detected by Indirect
ELISA closely based on standard techniques [22]. The
optimum dilutions of the antigen, serum and anti human
horse radish peroxidase (HRP) conjugate (Sigma-Aldrich,
USA) were determined by checkerboard titration with
known positive (pooled sera from 5 patients found posi-
tive for Cryptosporidium by staining techniques and con-
firmed with antigen detection and PCR) and 5 negativeBMC Infectious Diseases 2009, 9:179 http://www.biomedcentral.com/1471-2334/9/179
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control sera (apparently healthy individuals, excluded for
HIV seropositivity, Cryptosporidium and intestinal parasitic
infections by stool examination).
Each well of the 96-well microtitre plate (Nunc Inter Med,
Denmark) was coated with 100 μl optimum dilution of
the CCA in carbonate bicarbonate buffer. Plates were
incubated at 4°C overnight followed by washing thrice
with PBS containing 0.02% Tween-20 (PBST). The non
specific sites were blocked with 2%BSA in PBST and plate
was incubated at 37°C for 1 hr followed by washing thrice
with PBST. The doubling dilutions of the test, positive and
negative control sera (1:10-1:40) were prepared in 1%BSA
in PBST and 100 μl was added to each well. The plates
were incubated at 37°C for 1 hr and again washed thrice
with PBST followed by addition of 100 μl/well of opti-
mum dilutions of the anti-human IgG, IgM or IgA conju-
gated with horse radish peroxidase in 1%BSA in PBST and
incubated at 37°C for 1 hr. After the incubation, the plates
were washed thrice with PBST and Ortho Phenylene
Diamine (OPD) and H2O2 were added as substrate (100
μl/well). The plates were incubated in dark for 30 min and
then the reaction was stopped by adding 3 M H2SO4. The
absorbance of the contents of each well was read at 492
nm in an A4 ELISA reader (Eurogenetics, Tessenderle, Bel-
gium).
The cut off absorbance value (Optical Density) for each
dilution was determined by the mean absorbance of the 5
negative control sera plus 2 Standard Deviation (S.D). The
test sera giving absorbances that were equal to and above
the cut off O.D were considered ELISA positive at that
dilution under the test. Each sample was tested in dupli-
cate and mean O.D value of two tests was taken as reading
of that sample.
At the threshold titres, the sensitivity of the ELISA was cal-
culated [23] based on the assumption that all Cryptosporid-
ium positive cases from group I and III were true cases.
Ethical clearance
Ethical approval for the study was granted by the Ethical
Committee of the PGIMER, Chandigarh, India.
Statistical analysis
Difference between percentage positivity for antibody
response in the groups was determined by Fisher's exact
test. A p-value < 0.05 was taken as indicative of a statisti-
cally significant difference.
Results
Demographics
Demographic characters of the individuals for the study
are detailed out in Table 1. Out of 11 HIV seropositive
Cryptosporidium positive (Group I), 5 (45.5%) and out of
20 HIV seropositive Cryptosporidium negative (Group II)
patients, 9 (45%) had diarrhoea. All 10 HIV seronegative
Cryptosporidium  positive (Group III) patients had diar-
rhoea. Out of these, 4 (40%) had undergone kidney trans-
plantation (Group IIIa) and rest 6 were presumably
immunocompetent (Group IIIb) (Table 1).
On retrospective analysis, CD4 counts were available for
all patients in Group I and 17 out of 20 patients in Group
II. Median CD4 cell count was 182.5 cells/μl and 198.6
cells/μl for HIV seropositive Cryptosporidium positive and
HIV seropositive Cryptosporidium negative patients, respec-
tively (Table 1).
ELISA optimization
The optimum concentration of the C. parvum crude solu-
ble antigen (CCA) per well was 1 μg for IgG and IgA detec-
tion and 0.5 μg for IgM detection. The optimum conjugate
dilutions were 1:30,000 for IgG detection and 1:1,000 for
IgM and IgA detection. The optimum serum dilution was
found to be 1:20. Results at this dilution are used for fur-
ther discussion and analysis.
Table 1: Demographic profile of the individuals included for the study of anti-Cryptosporidium antibody responses
Group N Agea, years Males Females H/o diarrhoea bPost Tx CD4 counta, cells/μl
I HIV+Crypto+ 11 34.1 ± 8.4
(25-46)
7
(63.6%)
4
(36.4%)
5
(45.5%)
Nil 182.5 ± 119.3
(46-379)
II HIV+Crypto- 20 34.2 ± 10
(25-64)
15
(75%)
5
(25%)
9
(45%)
Nil 198.6 ± 143
(30-583)
III HIV-Crypto+ 10 26.2 ± 16.5
(3.5-46)
6
(60%)
4
(40%)
10
(100%)
4
(40%)
Not available
IV HIV-Crypto-(healthy) 20 26.9 ± 3.2
(23-35)
10
(50%)
10
(50%)
Nil Nil Not available
Total 61 30.5 ± 10.1
(3.5-64)
38
(62.3%)
23
(37.7%)
24
(39.3%)
4
(40%)
-
aMean ± SD (range)
bPost renal transplantationBMC Infectious Diseases 2009, 9:179 http://www.biomedcentral.com/1471-2334/9/179
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IgG antibody response
IgG antibody response was found positive in all 11
(100%) HIV seropositive Cryptosporidium positive (Gp I)
and 10 (100%) HIV seronegative Cryptosporidium positive
(Gp III) including all 4 post-transplant (Gp IIIa) patients.
Among Cryptosporidium negative subjects (Gp II, IV and V)
only three (12%) patients with other parasitic infections
showed positive response (Table 2).
IgM antibody response
IgM response was found positive in 2(18.2%) patients in
HIV seropositive Cryptosporidium positive (Gp I) and in 2
(20%) patients in HIV seronegative Cryptosporidium posi-
tive patients (Gp III). In the individuals not infected with
Cryptosporidium, only 2 (8%) patients infected with other
parasitic diseases showed antibody response (Table 2).
IgA antibody response
IgA response was found positive in 7(63.6%) patients in
HIV seropositive Cryptosporidium positive (Gp I) and in 5
(50%) in HIV seronegative Cryptosporidium  positive
patients (Gp III). In HIV seropositive Cryptosporidium neg-
ative (Gp II), 4 (20%) and in HIV seronegative Crypt-
osporidium  negative healthy (Gp IV), 2(10%) subjects
showed positivity while 2(8%) patients with other para-
sitic diseases (Gp V) were found positive (Table 2).
A positive IgG and IgA antibody response was observed in
significantly higher number of Cryptosporidium  infected
individuals (Gp I&III) compared to Cryptosporidium un-
infected individuals (Gp II, IV & V) (p values < 0.0001 for
IgG and <0.05 for IgA) irrespective of HIV status. There
was no difference in number of patients found positive for
IgG and IgA response between the two sub-groups in HIV
seronegative Cryptosporidium positive patients i.e. between
post-transplant (Gp IIIa) and presumably immunocom-
petent (Gp IIIb) patients (p > 0.05). No significant differ-
ence was observed in number of subjects showing positive
IgM response in any of the groups (Table 2). IgG and IgA
ELISA OD values for test samples, positive and negative
controls, cut-off for positivity and mean OD for each
group are shown in Fig 1.
Sensitivity and specificity
Sensitivity and specificity of IgG, IgM and IgA ELISA by
using Cryptosporidium parvum crude soluble antigen (CCA)
was 100% and 95.4%, 19% and 97% and 57.1% and
87.7%, respectively (Table 2)
Antibody responses Vs history of diarrhoea
Among the HIV seropositive Cryptosporidium  positive
patients, 11(100%), 2(18.2%) and 7(63.6%) were found
positive for IgG, IgM and IgA antibodies respectively and
out of these 5(45.5%), 0% and 4(57.1%) had a history of
diarrhoea. Number of IgG, IgM or IgA positive patients
with history of diarrhoea was not significantly different
from that of patients without history of diarrhoea (p >
0.05).
Antibody responses Vs CD4 counts
Among the HIV positive Cryptosporidium positive patients,
7(63.6%) out of 11 IgG positive patients had a CD4 count
of < 200 cells/ul whereas 1 out of 2 (50%) IgM positive
and 4 out of 7(57.1%) IgA positive patients had CD4
counts <200 cells/ul. Number of IgG, IgM or IgA positive
patients with CD4 counts <200 cells/μl was not signifi-
cantly different from that of patients with CD4 counts
>200 cells/μl (p > 0.05).
Table 2: Number of patients (%) showing positive antibody response to C. parvum crude soluble antigen (CCA)
Gp. Number studied Number positive
IgG IgM IgA
I HIV+Crypto+ 11 11 (100) 2 (18.2) 7 (63.6)
II HIV+Crypto- 20 Nil Nil 4 (20)
III HIV-Crypto+ 10 10 (100) 2 (20) 5 (50)
IIIa HIV-Crypto+ 4 4 (100) 1 (25) 1 (25)
IIIb HIV-Crypto+ 6 6 (100) 1 (16.7) 4 (66.7)
IV HIV-Crypto- 20 Nil Nil 2 (10)
V Other parasitic diseases 25 3 (12) 2 (8) 2 (8)
Sensitivity (%) 100 19 57.1
Specificity (%) 95.4 97 87.7
I vs II <0.0001 NS <0.05
I vs IV <0.0001 NS <0.01
PI  v s  V <0.0001 NS <0.01
II vs III <0.0001 NS <0.05
III vs IV <0.0001 NS <0.05
III vs V <0.0001 NS <0.05BMC Infectious Diseases 2009, 9:179 http://www.biomedcentral.com/1471-2334/9/179
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Discussion
In the present study, Cryptosporidium specific serum anti-
body (IgG, IgM and IgA) response was studied in dou-
bling serum dilutions (1:10-1:40) to assess and compare
the response in different study groups. We found that 1:20
dilution had the maximum sensitivity and specificity and
was subsequently taken for interpretation of results.
In the present study, IgG antibody response was found
positive in all 11 (100%) HIV seropositive Cryptosporidium
positive (Gp I) and 10 (100%) HIV seronegative Crypt-
osporidium  positive (Gp III) including 4 (100%) post-
transplant (Gp IIIa) patients while in the Cryptosporidium
negative groups (Gp II, IV and V), 3 (12%) patients with
other parasitic infections showed positive response. In the
present study, no difference was observed between
number of patients showing positive response in HIV
seropositive  Cryptosporidium  positive (Gp I) and HIV
seronegative Cryptosporidium positive (Gp III) patients (p
> 0.05). However, positive response was observed in sig-
nificantly higher number of Cryptosporidium infected indi-
viduals both HIV seropositive (Gp I) and seronegative
(Gp III) when compared to Cryptosporidium un-infected
HIV seropositive (Gp II), patients with other parasitic
infections (Gp V) and HIV seronegative healthy (Gp IV)
individuals. Our findings are similar to previous study
whereby serum IgG positivity was reported to be 100% in
AIDS patients with cryptosporidiosis, 87.7% in immuno-
competent patients with cryptosporidiosis, 5% in presum-
ably un-infected healthy individuals and 50% in patients
with other parasitic individuals [6]. Other studies have
also reported positive antibody response in 100% crypt-
osporidiosis patients with or without HIV [7,8]. Based on
assessment of mean OD values, previous studies [24-26]
found mean IgG levels higher in sera from HIV infected
patients with chronic cryptosporidiosis as compared to
healthy controls or HIV infected patients without crypt-
osporidiosis. In healthy individuals, IgG seropositivity
has been found to vary in number of individuals in differ-
ent parts of the world. IgG antibody response was found
positive in 86% in Australia [2], 26% in Britain [3] and
64% in Peru [4] and 64% in Venezuela [4] in healthy indi-
viduals. Although, studies regarding IgG antibody
response in transplant patients are not available, in the
present study, no difference in number of patients with
IgG positive response was observed between the two sub-
groups in HIV seronegative Cryptosporidium positive (post-
transplant and presumably immunocompetent) patients
(p > 0.05).
In the present study, IgM antibody response was found
positive in 2 (18.2%) HIV seropositive Cryptosporidium
positive (Gp I) and 2 (20%) HIV seronegative Crypt-
osporidium  positive (Gp III) including 1 (100%) post-
transplant (Gp IIIa) patient while in the Cryptosporidium
negative groups (Gp II, IV and V), 2 (8%) patients with
IgG (left panel) and IgA (right panel) response to Cryptosporidium parvum crude soluble antigen as seen by ELISA Figure 1
IgG (left panel) and IgA (right panel) response to Cryptosporidium parvum crude soluble antigen as seen by 
ELISA. Test sera were collected from HIV seropositive Cryptosporidium positive (Gp I), HIV seropositive Cryptosporidium neg-
ative (Gp II), HIV seronegative Cryptosporidium positive (Gp III), HIV seronegative Cryptosporidium negative apparently healthy 
(Gp IV) and HIV seronegative Cryptosporidium negative subjects infected with other parasites (Gp V). Dashed lines represent 
the cut-off OD for positivity.BMC Infectious Diseases 2009, 9:179 http://www.biomedcentral.com/1471-2334/9/179
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other parasitic infections showed positive response. No
significant difference was observed between number of
patients showing positive response in any of the group.
Based on assessment of mean OD values, previous studies
from France [24-26] found IgM levels higher in sera from
HIV infected patients with chronic cryptosporidiosis as
compared to healthy controls or HIV infected patients
without cryptosporidiosis. Another study found IgM lev-
els higher in sera from children with chronic crypt-
osporidiosis as compared to healthy controls [27]. IgM
serpositivity rate of 15.5% and 19.8% has been reported
in healthy children from Peru and Venezuela, respectively
[4]. Another study reported serum IgM positivity to be
15.4% in AIDS patients with cryptosporidiosis, 93.3% in
immunocompetent patients with cryptosporidiosis, 13%
in presumably un-infected healthy individuals and 22.6%
in patients with other parasitic individuals [6]. In contrast,
some studies have reported IgM positivity rate of 100% in
both HIV positive and negative patients with crypt-
osporidiosis [7,8].
In the present study, IgA antibody response was found
positive in 7 (63.6%) HIV seropositive Cryptosporidium
positive (Gp I) and 5 (50%) HIV seronegative Crypt-
osporidium positive (Gp III) including 1(25%) post-trans-
plant (Gp IIIa) patient while 4 (20%) HIV seropositive
Cryptosporidium negative, 2 (10%) HIV seronegative Crypt-
osporidium  negative healthy and 2 (8%) patients with
other parasitic diseases were found positive for IgA
response. A positive response was observed in signifi-
cantly higher number of Cryptosporidium infected individ-
uals when compared to Cryptosporidium  un-infected
irrespective of HIV status. In agreement with our findings,
a previous study has reported IgA positive response in
100% both in HIV positive and negative patients with
cryptosporidiosis [8]. Based on assessment of mean OD
values, previous studies found IgA levels higher in sera
from HIV infected patients with chronic cryptosporidiosis
as compared to healthy controls or HIV infected patients
without cryptosporidiosis [24-26] and in sera from chil-
dren with chronic cryptosporidiosis as compared to
healthy controls [27].
The difference in seropositivity in HIV infected as well as
healthy subjects in reports from different geographical
areas may be attributed to the duration of illness and type
of antigen used to study the antibody response.
No reports are available regarding prevalence of anti-
Cryptosporidium antibodies in India for comparison. How-
ever, varying rates of Cryptosporidium positivity in both
HIV (4.6-12%) and non-HIV (.06-13%) subjects are
reported from different geographical locations in India
[20].
Sensitivity and specificity of IgG ELISA by using Crypt-
osporidium parvum crude soluble antigen (CCA) was 100%
and 95.4%, respectively, in the present study, which is
similar to an earlier study [28] which reported the sensi-
tivity and specificity by using two antigens (recombinant
form of 27kDa and a partially purified fraction from 17
kDa oocysts antigen) as 90 and 92% and 90 and 94%,
respectively. In the present study, sensitivity and specifi-
city of IgM and IgA ELISA was found 19% and 97% and
57.1% and 87.7%, respectively. However, there are no
previous reports regarding sensitivity and specificity of
IgM or IgA ELISA in cryptosporidiosis.
On comparison of antibody response in HIV seropositive
patients with and without diarrhoea, the number of IgG,
IgM and IgA seropositive patients with history of diar-
rhoea was not significantly different from that of patients
without history of diarrhoea in both HIV seropositive
Cryptosporidium  positive and HIV seropositive Crypt-
osporidium negative groups. Earlier studies show contro-
versial role of IgG antibodies in cryptosporidiosis. Study
done in B-cells depleted BALB/c mouse model indicates
that the specific IgG antibody response does not play the
major role in the resolution of infection with Cryptosporid-
ium [29]. The fact that some AIDS patients with persistent
symptomatic infection with Cryptosporidium have a high
antibody titre to C. parvum also supports the theory that
specific serum antibody alone is not sufficient to control
the infection [9]. In contrast, Experimental study in
healthy volunteers reported that seropositivity was higher
in persons who were given infection dose >20 fold higher
than persons who were seronegative for Cryptosporidium
[30]. However, the authors suggest that serum antibody
may simply be a marker of an effective secretory and/or
cellular response to infection. In another study, Frost et al,
(2005) reported that in HIV positive individuals, a strong
IgG response to the 27-kDa antigen group was associated
with a reduced risk of diarrhea [31]. There are no reports
available regarding role of IgM antibodies in protection.
Previous study shows that HIV positive patients with
chronic cryptosporidiosis had higher levels of serum IgA
to soluble Cryptosporidium  antigen compared with HIV
positive persons who cleared the infection but secretory
IgA antibodies were higher in HIV positive persons who
cleared the infection as compared to HIV positive persons
with chronic cryptosporidiosis. This suggests that secre-
tory antibody but not serum antibody may be playing role
in protection. It has been suggested that secretory IgA is
responsible for the recovery from an effective immune
response at the mucosal surface [32]. However, the mech-
anism of diarrhoea in cryptosporidiosis is not well-under-
stood and is suggested to be due to disrupted mucosal
architecture and intestinal dysfunction resulting from the
infection and the host response to the infection besides
other factors [33,34] suggesting that antibody responsesBMC Infectious Diseases 2009, 9:179 http://www.biomedcentral.com/1471-2334/9/179
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may not be the only factors playing significant role in pro-
tection from symptomatic cryptosporidiosis, and other
innate and cellular immune responses may also be con-
tributing in the protection.
The number of IgG, IgM and IgA positive patients with
CD4 counts <200 cells/μl was not significantly different
from that of patients with CD4 counts >200 cells/μl in
both HIV seropositive Cryptosporidium positive and HIV
seropositive Cryptosporidium negative groups which shows
that production of antibodies may not be affected by CD4
counts in HIV patients. In agreement with our findings, a
previous study reported no significant difference in peak
antibody response to Cryptosporidium  antigens with
respect to HIV status, CD4 cell count or history of diarrhea
[35].
Conclusion
The present study showed specific serum IgG and IgA pro-
duction in patients infected with Cryptosporidium, both
HIV seropositive and seronegative as compared to unin-
fected subjects suggesting induction of Cryptosporidium
specific humoral immune response in infected subjects.
However, there was no difference in number of patients
with positive response in HIV seropositive or seronegative
groups indicating that HIV status may not be playing sig-
nificant role in modulation of Cryptosporidium  specific
antibody responses. Sensitivity of IgG ELISA in our study
was found to be higher as compared to IgM and IgA
ELISA. The number of patients with positive IgG, IgM and
IgA response was not significantly different in patients
with or without history of diarrhoea in HIV seropositive
Cryptosporidium  positive group thereby indicating that
Cryptosporidium specific antibody responses may not be
necessarily associated with protection from symptomatol-
ogy.
The limitation of the present study is that we have used
crude, soluble antigen of Cryptosporidium parvum, which
may contain a variety of proteins and nonprotein compo-
nents, both with and without antigenic properties, and
this may be the reason for the differences seen in the find-
ings. Moreover, few conclusions can be drawn because of
the small number of subjects in the study with the symp-
tomatic cryptosporidiosis. It will be worthwhile to study
and compare the responses of more subjects with the use
of more-specific antigenic fractions to ascertain the
present findings.
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